About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate Presentation
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
General meetings
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
Share capital and voting rights*
Share capital:
€2,779,188,40
Number of shares outstanding:
55,583,768
Total number of voting rights:
61,505,043
*As of April 30, 2023
All
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Report of the board of directors to the combined shareholders’ meeting - June 27, 2023
Download
Shareholders’ General Meeting Notice - June 27, 2023
Download